The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Gardasil is a vaccine, licensed for use in June 2006, by the FDA. It targets four strains of human papillomavirus (HPV) -- HPV-6, 11, 16, and 18. HPV-16 and HPV-18 account for about 70% of all ...

HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak ...

This shift in focus aims to create vaccines that can provide protection against a wider range of HPV types, including those not covered by existing vaccines. One innovative approach involves using ...

The U.S. Food and Drug Administration first approved Gardasil 9 in 2014 to prevent cancers and other diseases caused by nine HPV types. The vaccine is now cleared for use in women and men aged 9 ...

As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...

The approval makes GARDASIL the first HPV vaccine approved for use in males in China. GARDASIL is now indicated in China to prevent anal cancers caused by HPV Types 16 and 18, genital warts ...